Search research articles

ABOUT JoVE

Overview Leadership Blog JoVE Help Center

AUTHORS

Publishing Process Editorial Board Scope & Policies Peer Review FAQ Submit

LIBRARIANS

Testimonials Subscriptions Access Resources Library Advisory Board FAQ

RESEARCH

JoVE Journal Methods Collections JoVE Encyclopedia of Experiments Archive

EDUCATION

JoVE Core JoVE Business JoVE Science Education JoVE Lab Manual Faculty Resource Center Faculty Site

Terms & Conditions of Use

Related Concept Videos

Antiasthma Drugs: β2-Adrenoceptor Agonists

Antiasthma Drugs: β₂-Adrenoceptor Agonists

Bronchodilators are critical in managing asthma, a chronic respiratory condition characterized by airway constriction due to inflammation and hyper-reactivity. Specifically, bronchodilators ease this constriction by relaxing the bronchial muscles, facilitating easier breathing.
One class of bronchodilators includes β2-adrenoceptor agonists. These agents target the β2-adrenoceptors located on bronchial smooth muscle cells. By stimulating these receptors, β2-agonists induce...

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Antiasthma Drugs: Mast Cell Stabilizers and Anti-IgE Drugs

Asthma is a chronic respiratory condition for which new therapeutic avenues, including anti-inflammatory drugs like mast cell stabilizers and anti-IgE treatments, continue to be developed.
Mast cell stabilizers, such as cromolyn (also known as sodium cromoglycate) and nedocromil (Tilade), are effective drugs in asthma management. These stabilizers hinder histamine release by skillfully obstructing the activation of mast cells and other cellular entities. Notably, they navigate this task without...

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Antiasthma Drugs: Inhaled Corticosteroids and Glucocorticoids

Inhaled corticosteroids (ICS) are anti-inflammatory drugs used primarily in treating persistent asthma and providing long-term maintenance. They target the bronchial mucosa, the lining of the airways, to control inflammation, a critical factor in asthma progression and exacerbation.
ICS work through a multifaceted mechanism of action. They suppress the inflammatory response caused by the proliferation of TH cells. They also reduce the transcription of the IL-2 gene, which is involved in the...

Asthma: Pathogenesis and Management

Asthma: Pathogenesis and Management

Asthma is a chronic pulmonary condition involving inflammation of the airways, hyper-reactivity, and reversible obstruction of the airways. This condition can significantly impact a person's quality of life, making breathing difficult and leading to distressing symptoms.
Asthma is classified as allergic and non-allergic. Allergens such as dust mites, pollen, and pet dander trigger allergic asthma, while factors like cold air, intense emotions, or exercise can induce non-allergic asthma.

Drugs Used in Lower Respiratory Disorders: Overview

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...

Antiasthma Drugs: Leukotriene Modifiers

Antiasthma Drugs: Leukotriene Modifiers

Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by

Same author

Lower plasma resolvin D1 level and greater sputum eosinophilia characterize a cluster of severe asthma patients.

Respiratory research·2026

Same author

A cross-sectional study of oxidative stress pathway genotypes and their interactions with environmental pollutant levels identifies associations with gene expression and lung function.

EBioMedicine·2026

Same author

Dupilumab sustains efficacy despite LABA and ICS withdrawal in patients with asthma: A post hoc analysis.

The journal of allergy and clinical immunology. In practice·2026

Same author

Clinical phenotyping improves choices of biologics in asthma - Authors' reply.

Lancet (London, England)·2026

Same author

Bronchial thermoplasty for severe asthma: Systematic review and meta-analysis of benefits and harms.

The journal of allergy and clinical immunology. Global·2026

Same author

More Than One Way to Be Guilty: Eosinophils as Culprits and Messengers in Lung Disease.

The journal of allergy and clinical immunology. In practice·2026

Search research articles

Related Experiment Video

Updated: Jun 10, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Asthma Biologics: Lung Function, Steroid-Dependence, and Exacerbations.

Justin D Salciccioli¹, Elliot Israel²

¹Division of Pulmonary and Critical Care Medicine, Brigham and Women's Hospital, Harvard Medical School, 75 Francis Street, Boston, MA 02115, USA.

Immunology and Allergy Clinics of North America

|October 10, 2024

Summary

Targeted biologic therapies, including 6 monoclonal antibodies, have transformed asthma management. These advanced treatments offer personalized options for severe asthma beyond traditional therapies.

Keywords:

Asthma Bronchodilators Exacerbation Glucocorticoids

More Related Videos

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Related Experiment Videos

Last Updated: Jun 10, 2025

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Bronchial Thermoplasty: A Novel Therapeutic Approach to Severe Asthma

Published on: November 4, 2010

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Dry Powder and Nebulized Aerosol Inhalation of Pharmaceuticals Delivered to Mice Using a Nose-only Exposure System

Published on: April 6, 2017

Methodology for Sputum Induction and Laboratory Processing

Methodology for Sputum Induction and Laboratory Processing

Published on: December 17, 2017

Area of Science:

Pulmonology
Immunology
Pharmacology

Background:

Asthma management has evolved significantly with targeted therapies.
Severe and difficult-to-control asthma often requires advanced treatment strategies.

Purpose of the Study:

To review the current landscape of targeted biologic therapies for asthma.
To highlight the role of monoclonal antibodies in personalized asthma treatment.

Main Methods:

Review of existing literature on biologic therapies for asthma.
Identification and categorization of currently available monoclonal antibodies targeting asthma pathophysiology.

Main Results:

Six targeted monoclonal antibodies are currently available for asthma treatment.
These include anti-IgE, anti-IL-5, anti-IL-5 receptor alpha, anti-IL-4 receptor alpha, and anti-thymic stromal lymphopoietin agents.
Specific examples include omalizumab, mepolizumab, reslizumab, benralizumab, dupilumab, and tezepelumab.

Conclusions:

Targeted biologic therapies represent a revolution in severe asthma management.
These therapies offer personalized treatment options by targeting specific inflammatory pathways.
They provide alternatives to or adjuncts for bronchodilators and glucocorticoids in difficult-to-control asthma.